Opiant Pharma's Starts Dosing In Nasal Nalmefene Comparison Study For Remifentanil-Related Respiratory Depression

Loading...
Loading...
  • Opiant Pharmaceuticals Inc OPNT has dosed the first subjects in a head-to-head clinical study comparing the effectiveness of its investigational opioid antagonist nasal nalmefene (OPNT003) with nasal naloxone.
  • The Phase 1 study in healthy volunteers will evaluate the effectiveness of 3mg nasal nalmefene compared to 4 mg nasal naloxone to reverse the respiratory depression produced by the synthetic opioid remifentanil.
  • Top-line data from the trial are expected in the fourth quarter of 2021.
  • The development of OPNT003 is supported by grants from the National Institute on Drug Abuse, part of the National Institutes of Health, and the Biological Advanced Research and Development Agency.
  • Price Action: OPNT shares are up 1.4% at $11.3 in the premarket trading on the last check Tuesday.
Posted In: BiotechNewsHealth CareFDAGeneralBriefsRespiratory Depression
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...